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SUMMARY
Candida albicans is an opportunistic human pathogen that is capable of causing superficial and systemic infections in 
immunocompromised patients. Extracts of Sapindus saponaria have been used as antimicrobial agents against various organisms. 
In the present study, we used a combination of two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and matrix-assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) to identify the changes in protein abundance of C. 
albicans after exposure to the minimal inhibitory concentration (MIC) and sub-minimal inhibitory concentration (sub-MIC) of the 
butanolic extract (BUTE) of S. saponaria and also to fluconazole. A total of six different proteins with greater than 1.5 fold induction 
or repression relative to the untreated control cells were identified among the three treatments. In general, proteins/enzymes involved 
with the glycolysis (GPM1, ENO1, FBA1), amino acid metabolism (ILV5, PDC11) and protein synthesis (ASC1) pathways were 
detected. In conclusion, our findings reveal antifungal-induced changes in protein abundance of C. albicans. By using the previously 
identified components of the BUTE of S. saponaria (e.g., saponins and sesquiterpene oligoglycosides), it will be possible to compare 
the behavior of compounds with unknown mechanisms of action, and this knowledge will help to focus the subsequent biochemical 
work aimed at defining the effects of these compounds. 
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INTRODUCTION
Candida albicans is an opportunistic yeast that causes different forms 
of candidiasis in human hosts. Normally, C. albicans acts as a commensal 
organism in the gastrointestinal and genitourinary tracts; it can be isolated 
from approximately 70% of the population. Nevertheless, it can lead to 
disease, typically in immunocompromised and neutropenic patients1. 
Several antifungal agents have been used to treat Candida infections, 
but the effectiveness of many of these fungicides is still being evaluated. 
The most effective drugs for treating Candida infections are the azoles, 
polyenes and echinocandins. Natural compounds are a source of many 
active compounds that show multiple therapeutic effects2, and because 
the existing antifungals can have some toxicity, natural compounds have 
attracted attention. 
Species from the Sapindaceae family are known for their traditional 
medicinal use as diuretics, stimulants, expectorants, natural surfactants, 
sedatives, and vermifuges and for their use in the treatment of 
stomachaches and dermatitis in many parts of the world3. Sapindus 
saponaria L. (Sapindaceae), popularly known as “sabão-de-soldado” and 
“saboeiro”, is a medium-sized deciduous tree that occurs in the tropics 
of the Americas and India, where the fruit is used as a soap and as a 
medicine against ulcers, scabies, joint pain, inflammation4,5,6,7 and skin 
lesions caused by fungi8. Sapindus saponaria is a potential candidate for 
the treatment of candidiasis in vitro and in vivo9,10,11. 
In a recent study, members of our research group isolated and 
identified the main constituents of the n-BuOH extract (BUTE) of the 
pericarps of S. saponaria: two acetylated triterpene saponins, S1 and 
S2, and also an acyclic oligoglycoside (OGASA-01). The same group 
also demonstrated an excellent inhibitory in vitro activity of BUTE 
against Candida albicans and non-C. albicans isolated from patients 
with vulvovaginal candidiasis (VVC)11, indicating that this plant may be 
used as an antifungal agent for this pathology. In general, saponins have 
shown antifungal activity against C. glabrata, C. albicans, Trichosporon 
beigelii, Penicillium avellaneum, Pyricularia oryzae, Cryptococcus 
neoformans, Coccidioides immitis, and Saccharomyces cerevisiae, as 
well as against the dermatophytes Microsporum canis and Trichophyton 
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mentagrophytes12,13,14. Damke et al.9 showed that S. saponaria BUTE 
has antifungal activity in vivo using Wistar rats infected with azole-
susceptible C. albicans (SCA), azole-resistant C. albicans (RCA), and 
azole-resistant C. glabrata (RCG). According to Francis et al.10, the main 
mechanism for the antifungal activity of the saponins is their interaction 
with steroids of the fungal membrane.
Proteomics has been used to identify many proteins of Candida 
albicans under different conditions, such as adaptive responses to ambient 
pH, salt, cadmium and peroxide stress, the formation of biofilms and 
adaptive responses to antifungal agents15,16,17,18. The identification of these 
proteins is important because they can become targets for the development 
of novel therapeutic agents. 
In this study, we used a combination of two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) and the matrix-assisted 
laser desorption ionization-time of flight mass spectrometry (MALDI-
TOF MS) to identify the changes in protein abundance of C. albicans 
after exposure to the butanolic extract (BUTE) of Sapindus saponaria 
and to the commercial antifungal fluconazole. Despite speculation 
about the possible mechanisms of action of the saponins, there were no 
prior studies that demonstrated protein changes after Candida albicans 
exposure to S. saponaria BUTE.
MATERIAL AND METHODS
Antifungal agents: For the proteomic experiments, the butanolic 
extract (BUTE) of Sapindus saponaria was prepared at the Laboratory 
of Pharmacology of UEM as described below, and a stock solution was 
diluted in Milli-Q water at 18 mg/mL. The stock solution of fluconazole 
was prepared immediately before use in 100% DMSO at 500 mg/mL 
and stored at -20 °C. 
Plant and components: Dry fruit pericarps of S. saponaria were 
collected on the campus of the State University of Maringá, Paraná, 
Brazil (UEM). The plant was identified by staff members of the UEM 
Department of Botany, and an exsiccate was deposited in the Herbarium 
of this institution (HUM 11710). The dried pericarps of the fruits (450.0 
g) of S. saponaria were ground and extracted with EtOH: H2O (9:1) at 
room temperature by a process of dynamic maceration with constant 
mechanical stirring. The extraction was carried out in an amber flask at 
ambient temperature for 6 h per day on six consecutive days. The extract 
was concentrated under low pressure in a rotary evaporator at a temperature 
of 40 °C. After the solvent was eliminated, the extract was frozen in liquid 
nitrogen and lyophilized in a Martin Christ Alpha 1-2 freeze dryer. The 
lyophilized extract was stored in a closed plastic flask and kept frozen. 
Test of antifungal susceptibility: Drug susceptibility assays were 
carried out through the microdilution method with some adaptations for 
natural products19; fluconazole (FLU) (Pfizer Inc., New York, NY, USA) 
was dissolved in broth, and the lyophilized n-BuOH extract (BUTE) was 
dissolved in sterile distilled water to obtain a 10 mg/mL solution of each 
agent. For proteomic assays, the antifungal susceptibility test used an initial 
BUTE concentration of 18 mg/mL. The tests were carried out in triplicate 
in sterile plastic microplates (TPP Zellkultur TestPlate 96F, Switzerland). 
Stock solutions of FLU were prepared at 10 times the final 
concentration and diluted in RPMI-1640 with L-glutamine, bicarbonate-
free, supplemented with 2% dextrose and buffered to pH 7.0 with 0.165 
M of 3-(N-morpholino) propanesulfonic acid (MOPS). Each well of the 
microplate received an increasing concentration of FLU ranging from 
0.125 to 64 µg/mL. 
Regarding the BUTE test, 100-µL aliquots of RPMI were added to 
columns 2 to 11. Then, 100- µL aliquots of BUTE were added to columns 
1 and 2 of the microplates. From column 2 onward, 1:2 serial dilutions 
were performed to achieve maximal dilutions of 1:1,024.
For each isolate, negative (only RPMI), positive (RPMI plus 
inoculum, without antifungal addition), and diluent (alcohol and 
inoculum) controls were included on the plates. All the assays were 
carried out in triplicate. The treated microplates were incubated at 35 
°C for 48 h. The results of the fluconazole tests were determined in a 
microplate reader (Asys Hitech GmbH, Eugendorf/Austria), and the 
BUTE tests were evaluated by visual comparison using mirror reflex.
The MIC of FLU was defined as the first column with a significant 
growth reduction (~50%) when compared to the growth of the positive 
control. Concerning the BUTE, the results of the MIC were determined as 
the lowest concentration that was capable of inhibiting 100% of the yeast 
growth compared to the corresponding positive control. The MIC50 and 
MIC90 for FLU and BUTE were defined as the MIC capable of inhibiting 
50% and 90% of the isolate, respectively.
Scanning electron microscopy for the study of S. saponaria 
BUTE effect on C. albicans cells: Scanning electron microscopy was 
performed to verify the effect of S. saponaria BUTE on cell morphology 
of C. albicans. Aliquots of 1 mL of C. albicans ATCC 90028 cells were 
collected after 2 and 6 h of contact with 281.24 µg/mL of the extract, 
and the cells were prepared for scanning electron microscopy (SEM). 
This S. saponaria extract concentration corresponds to the MIC of S. 
saponaria BUTE observed for the inoculum size used for this assay. At 
the 6-h time point, cells were harvested and prepared for the proteomic 
assay. For the SEM, cells from 1 mL of culture were recovered by brief 
centrifugation and fixed in 2.5% glutaraldehyde for 2 h. The wells were 
washed twice with 0.1 M cacodylate and gradually dehydrated in ethanol. 
After coating with gold, the samples were examined with a Shimadzu 
SS-550 Superscan electron microscope. 
Organism and culture conditions for the proteome assay: C. 
albicans ATCC 90028 was cultured overnight in 20 mL of YPD broth 
(1% yeast extract, 2% peptone, 1% dextrose) in a temperature-controlled 
incubator at 30 °C. The cultures were diluted in 500 mL of fresh YPD 
medium to an optical density (OD) of 0.1 at 600 nm and subsequently 
grown at 30 °C until an OD of 0.2 was reached. After growth to an 
OD of 0.2, the cells were treated with 750 µg/mL fluconazole diluted 
in 0.5% DMSO, or 140.62 µg/mL or 281.24 µg/mL of the BUTE of S. 
saponaria, corresponding to the minimal sub-inhibitory (sub-MIC) and 
inhibitory concentrations (MIC), respectively. Control experiments were 
performed using 0.5% DMSO (the solvent for the fluconazole) added to 
the culture, and all cultures were kept at 30 °C in a shaker incubator at 
250 rpm (Nova Ética 430/RDBP) in a temperature-controlled incubator 
for 6 h. After the 6-h incubation, the ODs were measured.
Preparation of the protein extracts: Approximately 100 mg of C. 
albicans cells was collected by centrifugation in conical tubes for 5 min 
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at 4500 rpm (Hettich® Rotina 420). The pellet of cells was washed twice 
with ice-cold PBS buffer and once with ultrapure water. The cells were 
re-suspended in 500 µL of 7 M urea, 2 M thiourea, 4% CHAPS and 50 
mM DTT buffer containing 1x Protease Inhibitor Mix (GE Healthcare 
Bio-Science AB, Piscataway, MA, USA), and the suspension was 
sonicated on ice (30 bursts of 10 seconds ON, 30 seconds OFF with 40% 
amplitude). The lysates were clarified by centrifugation at 14,000 rpm 
(Eppendorf® 5430 R) for 20 min at 4 °C, and the protein concentrations 
were determined using Bradford assays21 and BSA as a standard.
Isoelectric focusing and 2DE analysis: Proteins were prepared 
for isoelectric focusing using the 2D Clean-Up kit (GE Healthcare 
Bio-Science AB, Piscataway, MA, USA) and re-suspended in DeStreak 
Rehydration Solution (GE Healthcare). The protein concentration was 
verified by the Bradford assay and adjusted to 250 µg in 250 µL of 
DeStreak Rehydration Solution with 0.5% IPG pH 3-10 buffer. The 
samples were applied to isoelectric focusing (IEF) strips (3-10 pH range, 
13 cm; GE Healthcare), which were overlaid with 0.6 mL DryStrip Cover 
Fluid (GE Healthcare) and rehydrated overnight at room temperature. 
Isoelectric focusing was performed using an IPGphor II IEF System (GE 
Healthcare Bio-Science AB, Uppsala, Sweden) at 20 °C, 500 V for 1 h, 
1,000 V for 1 h, 8,000 V for 2.5 h, and 8,000 V for 30 min.
Thereafter, the strips were equilibrated for 15 min with gentle shaking 
in a solution of 6 M urea, 2% SDS, 30% glycerol, 75 mM Tris-HCl 
pH 8.8, 0.002% bromophenol blue, and 1% DTT. The strips were then 
equilibrated for 15 min in a second buffer containing 2.5% iodoacetamide 
instead of DTT.
The equilibrated strips were overlaid on homogeneous 12% (1.0 mm 
thick) SDS-PAGE gels, electrophoresed at 100 V/ 10 mA/ 4 W per gel 
for 15 min and then 300 V/ 50 mA/ 60 W for approximately 4 h at 15 °C 
using a Hoefer SE 600 Ruby power supply (GE Healthcare Bio-Science 
AB, Uppsala, Sweden) with 12 µL of ColorPlus Prestained Protein Ladder 
(New England, Biolabs, Beverly, MA, USA). The proteins were detected 
by a modified Neuhoff Blue Silver Coomassie Colloidal Blue staining 
protocol22 and maintained in 5% acetic acid. The gels were scanned at 
an optical resolution of 300 dpi on a high-resolution image scanner (GE 
Healthcare, USA), and the images were analyzed using the ImageMaster 
Platinum 2D v6.0 software (GE Healthcare, USA). The differentially 
expressed proteins were selected for identification.
Protein Identification via In-gel Digestion and Mass Spectrometry: 
Protein spots were excised from the 2DE gels and subjected to in-gel 
digestion with sequencing-grade trypsin (Promega, USA) as described 
by Shevchenko23 with minor modifications; the digested proteins were 
then analyzed using mass spectrometry. After incubation at 37 °C for 
16 h, aliquots of each hydrolyzed sample were mixed with a saturated 
matrix solution of a-cyano-4-hydroxycinnamic acid, spotted onto MALDI 
target plates and allowed to air dry. Mass spectra (MS) were acquired 
using a MALDI-TOF/TOF Autoflex II spectrometer (Bruker Daltonics, 
Germany) with the MASCOT search engine (Matrix Science Ltd., UK) 
against the “Fungi” subset of the SwissProt database (http://www.expasy.
ch/sprot/) or NCBInr (http://www.ncbi.nlm.nih.gov/).
RESULTS
Morphological features of C. albicans after exposure to S. saponaria 
BUTE: SEM was performed to observe general morphological changes 
in C. albicans cells after exposure to S. saponaria BUTE (Fig. 1). 
Comparisons were made between the control C. albicans cells (untreated) 
and the C. albicans cells treated with a concentration of 281.24 µg/mL of 
BUTE. The untreated-cells were generally smooth-walled bodies after both 
2 h and 6 h of culture (Fig. 1A and 1B). The BUTE-treated cells presented 
surface irregularities, including convolutions (Fig. 1C and 1D). 
Comparison of the effects of fluconazole and the MIC and sub-MIC 
of S. saponaria BUTE on the protein expression pattern of C. albicans
Changes in the C. albicans proteome were analyzed by comparing 
cells treated with the MIC and sub-MIC of S. saponaria BUTE and cells 
treated with fluconazole with untreated control cells. The minimum 
inhibitory concentration (MIC) of S. saponaria BUTE (281.24 µg/mL) 
was determined at 0.2 O.D. The high concentration of fluconazole, 750 
µg/mL, is due to a large amount of inoculum and takes into account the 
conditions observed by Bruneau et al.24. Among the three conditions, a 
total of six proteins, not including individual protein isoforms, that had 
greater than 1.5-fold induction or repression relative to their amounts in 
untreated control cells were identified by in gel enzymatic digestion and 
MALDI-TOF-TOF (Fig. 2). The molecular proprieties and changes in 
the relative levels of expression are shown in Table 1, and the putative 
biological functions of these proteins are shown in Table 2. In general, 
the proteins are involved in glycolysis and amino acid metabolism.
Proteins that are responsive for the MIC of S. saponaria BUTE: 
The six proteins that were responsive for the MIC of BUTE of S. 
saponaria based on MALDI-TOF-TOF analysis are displayed in Fig. 
2B. Among these, two proteins were induced, and four proteins were 
repressed. The induced proteins were guanine nucleotide-binding protein 
subunit beta-like protein (ACS1) and likely mitochondrial ketol-acid 
reductoisomerase (ILV5). The expression of fructose-bisphosphate 
aldolase (FBA1), pyruvate decarboxylase (PDC11), enolase 1 (ENO1), 
and phosphoglycerate mutase (GPM1) was reduced. 
Proteins that are responsive for the sub-MIC of S. saponaria 
BUTE: The six proteins that were responsive to the sub-MIC of S. 
saponaria BUTE based on MALDI-TOF-TOF analysis are displayed in 
Fig. 2C. Among them, four proteins were induced, and 2 proteins were 
repressed. The induced proteins were guanine nucleotide-binding protein 
subunit beta-like protein (ACS1), phosphoglycerate mutase (GPM1), 
peroxisomal catalase (CTA1) and fructose-bisphosphate aldolase (FBA1). 
The expression of likely mitochondrial ketol-acid (ILV5) and fructose-
bisphosphate aldolase (FBA1) was decreased. 
Fluconazole-responsive proteins: The four proteins that were 
responsive to fluconazole according to MALDI-TOF-TOF analysis are 
displayed in Fig. 2D. Among them, one protein was induced, and three 
proteins were repressed. The induced protein was peroxisomal catalase 
(CTA1). The expression of fructose-bisphosphate aldolase (FBA1), 
pyruvate decarboxylase (PDC11) and phosphoglycerate mutase (GPM1) 
was decreased.
DISCUSSION
In the present study, we used a combination of 2D-PAGE and 
MALDI-TOF mass spectrometry to verify changes in protein expression 
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of C. albicans cells exposed to three treatments (MIC and sub-MIC of 
BUTE of S. saponaria and fluconazole). Proteins/ enzymes involved 
in glycolysis (GPM1, ENO1, FBA1), amino acid metabolism (ILV5, 
PDC11) and protein synthesis (ASC1) pathways were detected. It is 
difficult to obtain a clear interpretation of the mechanism of action of 
S. saponaria BUTE from this preliminary study of proteome changes. 
However, some observations can be made. Several of the biological 
processes are associated with carbohydrate metabolism, as observed 
by Martínez-Gomariz et al.25. Comparing the effects of the two S. 
saponaria BUTE concentrations on protein expression, we observed 
that more proteins had a decreased abundance after treatment with the 
MIC than with the sub-MIC. These included mainly proteins involved 
in glycolysis. Some proteins appeared as multiple spots on the gels, 
such as fructose-bisphosphate aldolase, pyruvate decarboxylase and 
phosphoglycerate mutase. The variation in the spots specifically occurs in 
the pI values. This may be caused by post-translational modifications such 
as phosphorylation. However, we cannot rule out that some of the spots 
may be due to the experimental procedure; this was observed for spot 
number 11, related to fructose-bisphosphate aldolase, which was found 
to be the same protein in spots 3 and 5 but with different pIs and MWs.
The ASC1 protein (guanine nucleotide-binding protein subunit beta-
like protein) was found to be upregulated in C. albicans after exposure 
to both the MIC and sub-MIC of S. saponaria BUTE, with increased 
values of 2.51 and 1.60 fold, respectively. Located at the head of the 
40S ribosomal subunit, in the vicinity of the mRNA exit channel, ASC1 
serves as a scaffold protein that can recruit other proteins to the ribosome. 
This protein is also a signal transducer that plays a pivotal role in cellular 
adhesion and virulence by regulating specific gene expression in C. 
albicans. It is also repressed in the stationary phase26 and presents a role 
in the induction of filamentation and biofilm formation27. This protein had 
no differential expression in cells treated with fluconazole. Given that 
fluconazole is a fungistatic antifungal and that C. albicans cells enter a 
stationary phase when they stop growing, ASC1 may be repressed due 
to fluconazole (data not shown). 
Enzymes involved in the glycolytic pathway such as FBA1 (fructose-
bisphosphate aldolase), PDC11 (pyruvate decarboxylase) and GPM1 
(phosphoglycerate mutase) were found to be downregulated in C. 
albicans cells treated with both the MIC of S. saponaria BUTE and 
fluconazole. ENO1 (enolase) was downregulated only in C. albicans cells 
treated with fluconazole. MALDI-TOF analysis of the sub-MIC-treated 
cell proteins showed three possible isoforms of FBA1; two of these 
isoforms were downregulated, and the other was upregulated. This protein 
is involved in a reversible reaction that is required for both glycolysis and 
gluconeogenesis. It is known that different antifungal agents have varying 
Fig. 1 - Scanning electron microscopy of C. albicans cells cultured for 2 h (A) and 6 h (B) without treatment (control) and for 2 h (C) and 6 h (D) in the presence of 281.24 µg/mL of S. 
saponaria BUTE. The majority of BUTE treated cells are distorted and have irregular surfaces.
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effects on the expression of GPM1 in C. albicans. Hoehamer et al.16 have 
shown that GPM1 mRNA increases during fluconazole exposure but is 
downregulated when cells are exposed to ketoconazole. One reasonable 
cause of the decreased expression of GPM1 in C. albicans cells exposed to 
fluconazole may be the growth phase of the harvested cells (the stationary 
phase). GPM1 mRNA levels increase during the exponential growth phase 
in yeast and then decrease to relatively low levels in the stationary phase. 
Additionally, the MIC of S. saponaria BUTE used in this work may have 
had a deleterious effect on C. albicans strains, preventing their growth 
and decreasing GPM1 expression. 
Shirtliff et al.28 used proteomic analysis to demonstrate that several 
glycolytic enzymes (e.g., glyceraldehyde 3-phosphate dehydrogenase, 
enolase, phosphoglycerate mutase and pyruvate kinase) were 
downregulated when C. albicans was exposed to farnesol, a natural 
15-carbon organic compound and acyclic sesquiterpene alcohol that 
is used by C. albicans as a quorum-sensing molecule, inhibiting 
filamentation. S. saponaria BUTE also contains sesquiterpenes, and one 
possible effect of this component may be the downregulation of these 
glycolytic enzymes. However, this interpretation remains speculative 
because we were unable to test the saponins and sesquiterpenes of S. 
saponaria BUTE separately. 
The protein ILV5 (likely mitochondrial ketol-acid reductoisomerase) 
had a differential expression in C. albicans after exposure to the MIC 
and sub-MIC of S. saponaria BUTE, with 2.09-fold upregulation and 
1.60-fold downregulation, respectively, compared to the untreated control 
cells. Ketol-acid reductoisomerase is described as an antigenic; GlcNAc, 
amino acid starvation (3-AT) induced; macrophage-repressed protein that 
is present in the exponential and stationary phases26,29,30.31. 
Peroxisomal catalase (CTA1) increased in abundance in C. albicans 
Fig. 2 - 2-D expression profiles of proteins from C. albicans ATCC 90028. (A) Untreated control, (B) treated with the MIC of S. saponaria BUTE, (C) fluconazole-treated, (D) treated with 
the sub-MIC of S. saponaria BUTE. Equal amounts of protein (250 µg) were loaded and separated on 13-cm IPG strips (pH 3–10), followed by electrophoresis on 12% SDS-PAGE gels in 
second-dimension electrophoresis. The gels were stained by Silver Coomassie Colloidal Blue. 
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Table 1
List of Sapindus saponaria and Fluconazole responsive proteins identified by MALDI-TOF mass spectrometry (difference at least 1.5-fold)
Spot no. MS/MS Score MS score Protein cover-
age % Fold change
1 Gel isoform pI Mr Protein ID
MIC S. saponaria
Upregulated Proteins
1 Nd 162 45 2.51 6.07 34533.62 ASC1
2 48 199 48/37 2.09 6.17 44935 ILV5
Downregulated Proteins
3 28 149 5/32 5.10 1 5.69 48/37 FBA1
4 Nd 162 21 1.82 1 5.39 62401.92 PDC11
5 Nd 168 34 2.46 2 5.69 39190.76 FBA1
6 26 82 4/19 4.06 1 5.79 27437.46 GPM1
7 5 312 2/43 3.10 2 5.39 62401.92 PDC11
8 43 159 3/26 1.93 5.54 47202.50 ENO1
9 22 136 4/28 1.60 2 5.79 27437.46 GPM1
Sub-MIC S. saponaria
Upregulated Proteins
1 Nd 162 45 1.60 6.07 34533.62 ASC1
6 26 82 4/19 1.84 5.79 27437.46 GPM1
10 51 115 1/21 2.05 6.03 55029.13 CTA1
11 Nd 252 53 1.87 1 5.69 39190.76 FBA1
Downregulated Proteins
2 48 199 48/37 1.60 6.17 44935 ILV5
3 28 149 5/32 4.13 2 5.69 39190.76 FBA1
5 Nd 168 34 2.72 3 5.69 39190.76 FBA1
Fluconazole
Upregulated Proteins
10 51 115 1/21 4.87 6.03 55029.13 CTA1
Downregulated Proteins
3 28 149 5/32 2.15 1 5.69 39190.76 FBA1
5 Nd 168 34 2.58 2 5.69 39190.76 FBA1
4 Nd 162 21 3.35 1 5.39 62401.92 PDC11
7 5 312 2/43 1.88 2 5.39 62401.92 PDC11
6 26 82 4/19 1.60 5.79 27437.46 GPM1
1Fold change: Change in expression between treated cells and control cells. Nd: Not done. The spot numbers are those indicated on Fig. 2. 
exposed to the sub-MIC of S. saponaria BUTE and fluconazole, but 
the MIC did not cause differential expression of this protein. It has 
been reported that CTA1 plays a role in resistance to oxidative stress32, 
virulence, core stress responses, and other functions that are regulated 
by fluconazole. 
In conclusion, our findings reveal antifungal-induced changes in 
protein abundance of C. albicans. By using the previously identified 
components of the S. saponaria BUTE, such as saponins and 
sesquiterpene oligoglycosides, it will be possible to compare the behavior 
of compounds with unknown mechanisms of action, which will help to 
focus subsequent biochemical studies. It is possible that some of these 
responsive proteins may represent potential targets for the development 
of novel therapeutic agents against this pathogenic fungus. 
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Table 2
Function of the proteins exhibiting a greater than 1.5-fold induction and repression which were identified by means of in-gel enzymatic  
digestion and MALDI-TOF-TOF 
Protein ID SwissProt or NCBI Accession number Metabolic process Function
ASC1 P83774 Ribosomal protein A component of the 40S ribosomal subunit and a signal 
transducer
ILV5 gi|68483473 Branched-chain amino acid  biosynthetic process Involved in branched chain amino acid biosynthesis.
FBA1 Q9URB4 Glycolysis
Catalyzes the aldol condensation of dihydroxyacetone phos-
phate with glyceraldehyde 3-phosphate to form fructose 
1,6-bisphosphate in gluconeogenesis and the reverse reaction 
in glycolysis.
PDC11 P83779 Glycolysis Catalyses the decarboxylation of pyruvic acid to acetaldehyde 
and carbon dioxide.
ENO1 P30575 Glycolysis
Catalyzes conversion of 2-phosphoglycerate to phosphoenol-
pyruvate during glycolysis and the reverse reaction during 
gluconeogenesis.
GPM1 P82612 Glycolysis Catalyses conversion of 2-phospho-D-glycerate to 3-phospho-D-glycerate.
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